Healthcare Private Placement and M&A Transactions Review Week Ending November 13 2022

Osler Diagnostics: The company raised $85 million of Series C venture funding from Braavos Investment Advisers, M&G, and Oxford Science Enterprises on November 7, 2022. Lansdowne Partners also participated in the round. The company is a developer of a blood sampling and testing device designed to test for biomarkers.

Faraday Pharmaceuticals: The company raised $52.8 million of venture funding from undisclosed investors on November 7, 2022. The company is a developer of novel therapeutics designed to offer elemental reducing agents.

Juvena Therapeutics: The company raised $41 million of Series A venture funding in a deal led by Mubadala Capital-Ventures and Horizons Ventures on an undisclosed date. Compound, Felicis Ventures, Intersect VC, BoxOne Ventures, Manta Ray Ventures, Transform VC, Alumni Ventures, Plum Alley Investments, Karl Pfleger, Jeff Dean, Bison Ventures and IRONGREY also participated in the round. The company is a developer of a biopharmaceutical drug discovery platform intended to discover novel protein-based therapeutics.

Nabsys: The company raised $38 million of Series B venture funding from Hitachi High-Technologies on November 9, 2022. The company is a developer of genome-mapping products designed to analyze whole genome mapping in high definition.

Ncardia: The company raised EUR 30 million of venture funding from undisclosed investors on November 7, 2022, putting the company’s pre-money valuation at EUR 80.00 million. The company is an operator of a biotechnology business created to provide technologies to expedite drug discovery and development processes.

Lipidio Pharmaceuticals: The company raised $20 million of Series A venture funding from FPWR, 3E Bioventures Capital, and Alethea Capital Management on November 10, 2022. Nancy Chang, John Maraganore, Brent Saunders, and other undisclosed investors also participated in the round. The company is a developer of therapeutic drugs designed to treat diseases associated with excess body fat.

NRG Therapeutics: The company raised GBP 16 million of Series A venture funding in a deal led by Omega Funds on November 9, 2022. Parkinsons UK and Brandon Capital also participated in the round. The company is an operator of a drug discovery platform intended to develop therapeutic approaches to restore mitochondrial function.

CuraSen: The company raised $15 million of venture funding from undisclosed investors on November 9, 2022. The company is an operator of a biopharmaceutical business intended for the development of novel treatments for neurodegenerative diseases.

CranioVation: The company raised $14 million of venture funding from undisclosed investors on November 9, 2022. The company is a developer of a surgical device designed to treat aggressive brain tumors using light delivered via a minimally invasive device.

MapLight Therapeutics: The company raised $12 million of venture funding from undisclosed investors on November 10, 2022. The company is an operator of a biopharmaceutical business intended to discover novel treatments for brain disorders.

Metabolon: The company raised $10.0 million of venture funding from undisclosed investors on November 10, 2022. The company is a developer of analytical software designed to decipher discrete chemical signals from genetic and non-genetic factors to reveal biological pathways.

Wesper: The company raised $7.5 million in Series A venture funding from Ceros Financial Services and Krillion Ventures on November 8, 2022, putting the company’s pre-money valuation at $38 million. The company is a developer of a topical patch for sleep medicine.

---

ARS Pharmaceuticals / Silverback Therapeutics: The company acquired Silverback Therapeutics through a reverse merger for an estimated $265 million, resulting in the combined entity trading on the Nasdaq stock exchange under the ticker symbol $SPRY on November 8, 2022. ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis.

Baergic Bio / Avenue Therapeutics: The company was acquired by Avenue Therapeutics for an undisclosed amount on November 8, 2022. The company is a provider of biopharmaceutical services designed to focus on the commercialization of novel therapeutics.

Cell IDx / Leica Biosystems: The company was acquired by Leica Biosystems for an undisclosed amount on November 8, 2022. The company is an operator of a biotechnology business intended to provide multiplex immunohistochemistry solutions for research and diagnostics.

Clarion Healthcare / Lumanity: The company was acquired by Lumanity, via its financial sponsor Arsenal Capital Partners, through an LBO on November 8, 2022 for an undisclosed amount. The company is a provider of life sciences strategy and organizational consultancy services intended for therapeutic businesses.

Expression Systems / ANGUS Chemical Company: The company was acquired by ANGUS Chemical Company, via its financial sponsors Ardian and Golden Gate Capital, through an LBO on November 9, 2022 for an undisclosed amount. The company is a provider and supplier of baculovirus titering service to facilitate a client’s research and development programs.

Inscopix / Bruker: The company was acquired by Bruker for an undisclosed amount on November 8, 2022. The company is a developer of a brain imaging device designed to transform real-time brain mapping with miniature microscope intervention.

NeuTrace / Anumana: The company was acquired by Anumana for an undisclosed amount on November 7, 2022. The company is a provider of a cardiac electrophysiology platform intended to offer advanced research, diagnosis, and treatment for prospective patients with abnormal heart rhythms.

Targenomix / Bayer: The company was acquired by Bayer for an undisclosed amount on November 10, 2022. The company is an operator of a target identification business intended to identify the mode of action of a lead molecule in a biological system.

---